Mark C. McKenna
Independent Non-Executive Vice ChairmanMr. Mark C. McKenna is Independent Director of TCGX Acquisition Corp. II from October 15, 2026. Mr. McKenna is Strategic Advisor of Ventyx Biosciences, Inc. from December 2025. He serves as Independent Director of Helix Acquisition Corp. III since January 22, 2026. Mr. McKenna is Independent Non-Executive Director of New Amsterdam Pharma Company N.V. from July 16, 2024 and serves as its Independent Non-Executive Vice Chairman. Mr. McKenna served as Director at Helix Acquisition Corp. II since February 13, 2024 until August 2025. He is the Founder, Chairman, Chief Executive Officer and Executive Director at Mirador Therapeutics. He served as an Independent Chairman of the Board at Apogee Therapeutics, Inc. since August 2023 until September 3, 2026. He serves as Independent Director at Perceptive Capital Solutions Corp. since June 2024. He served as Chairman of the Board at Prometheus Biosciences, Inc. since August 2021 until June 16, 2023. He serves as Director of Rebalance Health, Inc. He is Director of Spyre Therapeutics, Inc. from February 01, 2024. He served as Executive Chairman of Prometheus Laboratories Inc. until June 2023. Mr. McKenna serves as Chief Investment Officer and Managing Director of McKenna Capital Partners. He served as a President, Chief Executive Officer and Director at Prometheus Biosciences, Inc. since September 2019 until June 16, 2023. He served as President and Chief Executive Officer of Salix Pharmaceuticals, Inc. (Salix), a wholly owned subsidiary of Bausch Health Companies, Inc. (Bausch), from March 2016 through August 2019 and was its SVP & GM. He served as a Senior Vice President and General Manager of Vision Care at Bausch & Lomb Incorporated until August 2016 and also served as its Vice President. Prior to joining Salix, he spent more than a decade with Bausch + Lomb, he was Senior Vice President/General Manager of its U.S. Vision Care business. Prior to Bausch + Lomb, he held several roles of increasing responsibility at Johnson & Johnson. He began his career at Johnson & Johnson from 2002 to 2006. He has served as a Member of the Board of Rebalance Health, Incorporated since December 2021. He holds a B.S. in Marketing from Arizona State University and an M.B.A. from Azusa Pacific University. He also completed the Wharton’s Fellows program at the University of Pennsylvania school of business. Mr. McKenna serves as a venture partner at Arch Venture Partners and Senior Advisor at Fairmount Funds Management LLC, a healthcare investment firm, since October 2023.has B.S. in Marketing from Arizona State University. Mr. McKenna has M.B.A. in Management from Azusa Pacific University in 2008.
Positions
- Company NameNewAmsterdam Pharma Company N.V.Stock CodeNAMSPositionIndependent Non-Executive Vice ChairmanRelated SecuritiesColleagues
- MHMichael Harvey DavidsonCEO, President & Executive Director
- WHWilliam H. LewisIndependent Chairman of Board of Directors
- JJJohannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director
- MAMayur Amrat SomaiyaChief Financial Officer
- RWRobert W. GunningPrincipal Accounting Officer, VP & Controller
- MPMatthew PhilippeExecutive VP & Head of Investor Relations
- MCMark C. McKennaIndependent Non-Executive Vice Chairman
- JWJohn W. SmitherIndependent Director
- Company NameHelix Acquisition Corp. IIIStock CodeHLXCPositionIndependent Director
- Company NameTCGX Acquisition Corp. IIStock CodeTCXBPositionIndependent Director
